Regeneron Pharmaceuticals REGN Additional Paid-In Capital
Additional Paid-In Capital at other companies
Other financials
Where this comes from
Reported directly by Regeneron Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:AdditionalPaidInCapital.
The official record: Regeneron Pharmaceuticals’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →
Ask your AI about Regeneron Pharmaceuticals's additional paid-in capital.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Regeneron Pharmaceuticals's additional paid-in capital?
- Regeneron Pharmaceuticals (REGN) reported additional paid-in capital of $14.4B in Q1 2026.
- How has Regeneron Pharmaceuticals's additional paid-in capital changed year-over-year?
- Regeneron Pharmaceuticals's additional paid-in capital increased by 9.2% year-over-year, from $13.19B to $14.4B.
- What is the long-term trend for Regeneron Pharmaceuticals's additional paid-in capital?
- Over 5 years (2020 to 2025), Regeneron Pharmaceuticals's additional paid-in capital has grown at a 15.8% compound annual growth rate (CAGR), from $6.72B to $14B.
- What does additional paid-in capital mean?
- Capital received from shareholders in excess of par value — the premium investors paid over the nominal value of shares at issuance, plus stock-based compensation effects.